Company profile
Humacyte, Inc. logo

Humacyte, Inc.

Pipeline6 assets

  • Symvess (ATEV)Symvess / Acellular Tissue Engineered Vessel / Vascular Disease
    Vascular trauma repairApprovedFDA Approved (Dec 2024)United StatesArteriovenous access for hemodialysisPhase 3V007 met primary endpoints; V012 ongoing; sBLA planned H2 2026United StatesPeripheral artery disease (PAD)Phase 2Completed Phase 2 trials and expanded access; positive limb salvage dataUnited StatesEurope
  • CTEVCoronary Tissue Engineered Vessel / Cardiovascular Disease
    Coronary artery bypass grafting (CABG)PreclinicalPositive NHP data; IND submitted; first-in-human planned H2 2026United States
  • Biovascular Pancreas (BVP)Biovascular Pancreas™ / Bioengineered Organ / Diabetes
    Type 1 diabetesPreclinicalPositive preclinical data; NHP studies planned; first-in-human planned 2027
  • Urinary ConduitAdvanced Tissue Construct / Urology
    Urinary diversion after cystectomyPreclinical
  • Tracheal ReplacementAdvanced Tissue Construct / Otolaryngology
    Tracheal replacementPreclinical
  • Esophageal ReplacementAdvanced Tissue Construct / Gastroenterology
    Esophageal replacementPreclinical

Latest news19 items

All news

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current

Results Call • Phase 3Results call Mon, Jun 15, 2026, 5:00 PM ET

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012’s primary endpoint and was observed to have superior catheter-free days (p=0.00070) compared to autologous arteriovenous (AV)

Trial Results • Phase 3SVS VAM presentation Thu, Jun 11, 2026

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim

Interim Data • Phase 3V012 Phase 3 interim results Thu, Jun 11, 2026

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and

Interim Data • Phase 3V012 Phase 3 interim results at SVS VAM Thu, Jun 11, 2026

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience and perspective to Humacyte’s corporate leadership team as clinical adoption of Symvess® ramps up

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as

Humacyte, Inc. • Endpoint Arena